A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Primary and study completion moved earlier from Nov 2027 to Aug 2027
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 8 of 13 entries
    • Site details revised at 55 of 55 sites
  2. Site details revised at 48 of 55 sitesv15
  3. Site contacts updated at 13 of 55 sitesv14
  4. Study sites revised (55)v13
  5. Site details revised at 1 of 55 sitesv12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary and study completion dates: Feb 2027 to Nov 2027
    • Site details revised at 1 of 55 sites
    v11
  2. Study sites: 56 to 55v10
  3. Study sites: 57 to 56v9
  4. Site details revised at 2 of 57 sitesv8
  5. Site details revised at 2 of 57 sitesv7
  6. Primary and study completion dates: Jan 2027 to Feb 2027
    • Site details revised at 6 of 57 sites
    v6
  7. Study sites: 56 to 57v5
  8. Study sites: 55 to 56v4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 31 to 55
    • Start date changed from estimate of Mar 2025 to Mar 6, 2025
    v3
  10. Study title expanded, about 2 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Psoriasis
593 trials monitored
See 24 trials at risk
Psoriatic Arthritis
212 trials monitored
See 10 trials at risk
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Trial Details
NCT Number NCT06864026
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Psoriatic Arthritis, Overweight or Obesity
Related terms Arthritis, Psoriatic, Obesity, Overweight
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov